Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrografin for Bowel Obstruction in Gastroschisis
NCT03334578Phase 4Withdrawn
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of diatrizoate meglumine + diatrizoate sodium in bowel obstruction and gastroschisis (2 arms). Primary endpoints: Time to Start Feeds up to 6 months and Time to Reach Full Feeds up to 6 months. Planned start Aug 2018; status: withdrawn.
02
Drugs
diatrizoate meglumine + diatrizoate sodium
03
Conditions
bowel obstructiongastroschisis
Beyond the preview
Go deeper on NCT03334578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334578.